Raymond James initiated coverage of Spyre Therapeutics (SYRE) with a Strong Buy rating and $80 price target Spyre is developing next-generation, long-acting antibodies for validated targets, says the analyst, who believes the company is “uniquely positioned to capitalize” on the combination therapy opportunity in inflammatory bowel disease and expansion of TL1A therapies into rheumatic diseases.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Buy Rating on SYRE: Early SPY001 Outperformance, Broad IBD Opportunity, and Catalyst‑Rich Path Support Higher $80 Target
- Spyre Therapeutics price target raised to $80 from $65 at Wedbush
- Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen
- Spyre Therapeutics price target raised to $106 from $49 at Leerink
- Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data